Glaucoma

Ophthalmology·MeSH: Glaucoma, Open-Angle

Prevalence

3000.0 / 100K

Incidence

150.0 / 100K/yr

25 drugs in development·18 companies·11 clinical trials

Drug Pipeline by Phase

Approved(15)

Drug	Company
acetazolamide	ACHIEVE LIFE SCIENCES, INC. (ACHV)
acetazolamide	Greenwich LifeSciences, Inc. (GLSI)
acetazolamide	Prestige Consumer Healthcare Inc. (PBH)
acetazolamide	MANNKIND CORP (MNKD)
acetazolamide	ACADIA PHARMACEUTICALS INC (ACAD)
acetazolamide	Mylan II B.V. (MYL)
bimatoprost	Amneal Pharmaceuticals, Inc. (AMRX)
brimonidine	Amneal Pharmaceuticals, Inc. (AMRX)
cosopt pf	AKORN INC (AKRX)
rescula	SUCAMPO PHARMACEUTICALS, INC. (SCMP)
rhopressa	AERIE PHARMACEUTICALS INC (AERI)
rocklatan	AERIE PHARMACEUTICALS INC (AERI)
solx gold shunt	SPOTLIGHT INNOVATION INC. (STLT)
timolol	Amneal Pharmaceuticals, Inc. (AMRX)
zioptan	AKORN INC (AKRX)

Phase 3(2)

Drug	Company
bim-drs	SpyGlass Pharma Inc. (SGP)
OTX-TIC	OCULAR THERAPEUTIX, INC (OCUL)

Phase 2(2)

Drug	Company
Durysta, Bimatoprost Intracameral Implant 10 µg	OCULAR THERAPEUTIX, INC (OCUL)
sbi-100 ophthalmic emulsion	Skye Bioscience, Inc. (SKYE)

Preclinical(3)

Drug	Company
inm-088	InMed Pharmaceuticals Inc. (INM)
man 01	Q BioMed Inc. (QBIO)
man-01	Q BioMed Inc. (QBIO)

Phase 1/Phase 2(1)

Drug	Company
agn-193408 sr	AbbVie Inc. (ABBV)

Phase 4(2)

Drug	Company
artificial tears	GH Research PLC (GHRS)
netarsudil ophthalmic solution 0.02%	GH Research PLC (GHRS)

BioSniper tracks 25 drugs in development for Glaucoma across 18 companies.

There are 11 clinical trials targeting Glaucoma tracked by BioSniper.

The estimated prevalence of Glaucoma is approximately 3000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.